

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A03/2017 OS

DESPATCHED ON 28TH MARCH 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A68; B35, B42; Cw4, Cw17; DR4, DR18; DQ4, DQ8

| | | | | Summary of Results | | | | | | | | | | | | |
|---|-----------------|---------------------|-------------------|--------------------|-----------------|-----------------|------------------|-----------------|-----------------|-----------------|-----------------|------------------|------------------|------------------|------------------|---|
| | | | | PBL | | | | T-Cells | | | | B-Cells | | | | |
| Total tested | 13 | 12 | 13 | 12 | 38 | 38 | 38 | 38 | 33 | 35 | 34 | 31 | | | | |
| Positive | 1 | 6 | 1 | 0 | 0 | 6 | 2 | 0 | 0 | 31 | 26 | 6 | | | | |
| Negative | 12 | 6 | 12 | 12 | 38 | 32 | 36 | 38 | 33 | 4 | 8 | 25 | | | | |
| NT/Equivocal | 2 | 3 | 2 | 3 | 0 | 0 | 0 | 0 | 6 | 4 | 5 | 8 | | | | |
| % Positive | 7.7% | 50.0% | 7.7% | 0.0% | 0.0% | 15.8% | 5.3% | 0.0% | 0.0% | 88.6% | 76.5% | 19.4% | | | | |
| % Negative | 92.3% | 50.0% | 92.3% | 100.0% | 100.0% | 84.2% | 94.7% | 100.0% | 100.0% | 11.4% | 23.5% | 80.6% | | | | |
| Consensus | Negative | Not Assessed | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | | | |
| HLA Antibody Specificity (Defined By CDC) | A32 B44 DR7 | DQ3 | DR3 DR5 DR6 | A10 B16 DQ1 | A32 B44 DR7 | DQ3 | DR3 DR5 DR6 | A10 B16 DQ1 | A32 B44 DR7 | DQ3 | DR3 DR5 DR6 | A10 B16 DQ1 | | | | |
| Lab No. | PBL Assessment | T Cell Assessment | B Cell Assessment | Without DTT | | | | Without DTT | | | | Without DTT | | | | Comments |
| | | | | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Serum 1 | Serum 2 | Serum 3 | Serum 4 | |
| 101 | YES | YES | YES | NT | NT | NT | NT | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Negative | Results not conclusive |
| 112 | YES | YES | YES | | | | | Negative | Positive | Positive | Negative | Negative | Positive | Positive | Negative | Dealted delivery. Low B-cell viability |
| 114 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Equivocal | Equivocal | Equivocal | Equivocal | |
| 116 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Positive | |
| 119 | YES | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Positive | |
| 120 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Positive | |
| 128 | YES | | | Negative | Positive | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 133 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 139 | YES | YES | YES | Negative | Positive | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 143 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 145 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 147 | YES | YES | YES | Negative | Positive | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 154 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Negative | |
| 157 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 159 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 162 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 163 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 169 | | YES | YES | | | | | Negative | Positive | Positive | Negative | Equivocal | NT | Positive | Positive | Low viability and aggregates cells that not allowed a conclusive result |
| 181 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 186 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Positive | |
| 189 | YES | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Positive | |
| 190 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 193 | YES | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Equivocal | |
| 194 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Equivocal | Cells arrives clustered in the sample |
| 195 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 197 | | YES | YES | | | | | Negative | Positive | Negative | Negative | Negative | Positive | Positive | Negative | |
| 204 | | YES | YES | | | | | Negative | Positive | Negative | Negative | Negative | Positive | Equivocal | Equivocal | Very low B-cell viability |
| 206 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Equivocal | Serum 4 B-cells - reaction between 2 and 4 |
| 209 | YES | | YES | Negative | Negative | Negative | Negative | | | | | Negative | Positive | Positive | Negative | Low number of B-cells |
| 216 | YES | | | Positive | Negative | Negative | Negative | | | | | Negative | Positive | Positive | Negative | |
| 223 | | YES | YES | | | | | Negative | Positive | Negative | Negative | NT | NT | NT | NT | Low b-cell viability |
| 227 | | YES | YES | | | | | Negative | Negative | Negative | Negative | NT | Positive | NT | NT | Technical failure |
| 229 | YES | | | | | | | | | | | | | | | No results returned |
| 232 | YES | | | NT | NT | NT | NT | | | | | | | | | Samples held in customs |
| 235 | YES | | | Negative | NT | Negative | Negative | | | | | | | | | Serum 2 is haemolysis |
| 238 | YES | YES | YES | Negative | Positive | Positive | Equivocal | Negative | Negative | Negative | Negative | Equivocal | Positive | Positive | Positive | Serum 1 DQ6 MFI 7000 + DP6 MFI 7000 |
| 239 | YES | YES | YES | Negative | Positive | Negative | Negative | Negative | Positive | Negative | Negative | Negative | Positive | Negative | Negative | |
| 245 | YES | YES | YES | Negative | Positive | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 252 | YES | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 259 | YES | | | | | | | | | | | | | | | No results returned |
| 260 | | YES | YES | | | | | Negative | Negative | Negative | Negative | NT | NT | NT | NT | Low B-cell viability |
| 268 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 284 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 292 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Negative | |
| 293 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 294 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 297 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Positive | |
| 321 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 351 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Serum 2 was hemolyzed |

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A03/2017 OS

DESPATCHED ON 28TH MARCH 2017

| Lab No. | PBL without DTT | | | | T-cell without DTT | | | | B-cell without DTT | | | | Cell viability % | | |
|---------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|------------------|---------|---------|
| | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | PBL | T-cells | B-cells |
| 101 | | | | | 1 | 1 | 1 | 1 | 1 | 8 | 1 | 1 | | | |
| 112 | NT | NT | NT | NT | | | | | | | | | 90 | | |
| 114 | | | | | 1 | 4 | 4 | 1 | 1 | 8 | 4 | 1 | | | |
| 116 | | | | | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | | 95 | 30 |
| 119 | 1 | 1 | 1 | 1 | | | | | | | | | 90 | | |
| 120 | | | | | 1 | 1 | 1 | 1 | 1 | 8 | 4 | 4 | | 100 | 100 |
| 128 | 1 | 4 | 1 | 1 | | | | | | | | | 90 | | |
| 133 | | | | | - | - | - | - | - | 8 | 8 | - | 95 | 95 | 95 |
| 139 | 1 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 1 | 80 | 80 | 80 |
| 143 | | | | | 1 | 1 | 1 | 1 | | | | | 90 | | |
| 145 | | | | | - | - | - | - | - | - | - | - | 100 | 100 | |
| 147 | 1 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 1 | 100 | 100 | 100 |
| 154 | | | | | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 99 | | |
| 157 | | | | | 1 | 1 | 1 | 1 | 1 | 8 | 6 | 1 | | 90 | 80 |
| 159 | | | | | 1 | 1 | 1 | 1 | 1 | 8 | 4 | 1 | | 100 | 85 |
| 162 | | | | | - | - | - | - | - | 8 | 8 | - | | 100 | 100 |
| 163 | | | | | 1 | 1 | 1 | 1 | 1 | 8 | 6 | 1 | | 98 | 98 |
| 169 | | | | | 1 | 4 | 4 | 1 | Equivocal | NT | 8 | 6 | | 90 | 90 |
| 181 | | | | | 1 | 1 | 1 | 1 | 2 | 8 | 8 | 2 | | 95 | 95 |
| 186 | | | | | 0 | 0 | 0 | 0 | 0 | 8 | 8 | 8 | | 95 | 90 |
| 189 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 95 | | |
| 190 | | | | | 1 | 1 | 1 | 1 | 10 | 100 | 50 | 30 | | 99 | 80 |
| 193 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 4 | 1 | 99 | 99 | 97 |
| 194 | | | | | - | - | - | - | - | - | - | Equivocal | | | |
| 195 | | | | | 2 | 2 | 2 | 2 | 2 | 6 | 6 | 4 | | 85 | 85 |
| 197 | | | | | - | Weak | - | - | - | - | Weak | - | | 80 | 80 |
| 204 | | | | | 1 | 4 | 1 | 1 | 6 | 8 | 6 | 6 | | 90 | 50 |
| 206 | | | | | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 4 | | 90 | 90 |
| 209 | 1 | 1 | 1 | 1 | | | | | 1 | 8 | 6 | 1 | 90 | | 85 |
| 216 | 1 | 1 | 1 | 1 | | | | | | | | | 95 | | |
| 223 | | | | | 2 | 4 | 1 | 1 | NT | NT | NT | NT | | 95 | 70 |
| 227 | | | | | - | - | - | - | NT | 8 | NT | NT | | 90 | 90 |
| 229 | | | | | | | | | | | | | | | |
| 232 | | | | | NT | NT | NT | NT | | | | | | | |
| 235 | 1 | NT | 1 | 1 | | | | | | | | | 85 | | |
| 238 | 1 | 4 | 4 | 2 | 1 | 1 | 1 | 1 | 2 | 8 | 6 | 4 | 90 | 90 | 70 |
| 239 | - | ++++ | - | - | - | ++++ | - | - | - | ++++ | - | - | 90 | 90 | 90 |
| 245 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 4 | 1 | 100 | 100 | 100 |
| 252 | 2 | 2-4 | 2 | 2 | | | | | 4 | 6-8 | 6 | 4 | 80 | | 70 |
| 259 | | | | | | | | | | | | | | | |
| 260 | | | | | - | - | - | - | NT | NT | NT | NT | | 90 | 10 |
| 268 | | | | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | 95 | 50 |
| 284 | | | | | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 2 | | 99 | 85 |
| 292 | | | | | - | - | - | - | - | 8 | - | - | | 80 | 30 |
| 293 | | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | 70 | 70 |
| 294 | | | | | 0 | 0 | 0 | 0 | 0 | 8 | 8 | 2 | | 100 | 85 |
| 297 | | | | | 1 | 2 | 1 | 1 | 1 | 8 | 8 | 6 | 90 | 90 | 90 |
| 321 | | | | | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 1 | | 97 | 97 |
| 351 | | | | | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 100 | | |

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A03/2017 OS

DESPATCHED ON 28TH MARCH 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A68; B35, B42; Cw4, Cw17; DR4, DR18; DQ4, DQ8

| | | | | Summary of Results | | | | | | | | | | | | | |
|---|-----------------|---------------------|-------------------|--------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|----------|-----------|-----------|---|-------------------------------------|
| | | | | PBL | | | | T-Cells | | | | B-Cells | | | | | |
| Total tested | 12 | 11 | 12 | 11 | 34 | 34 | 34 | 34 | 29 | 32 | 31 | 29 | | | | | |
| Positive | 1 | 5 | 1 | 1 | 0 | 3 | 1 | 0 | 1 | 29 | 26 | 5 | | | | | |
| Negative | 11 | 6 | 11 | 10 | 34 | 31 | 33 | 34 | 28 | 3 | 5 | 24 | | | | | |
| NT/Equivocal | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 5 | 3 | 4 | 6 | | | | | |
| % Positive | 8.3% | 45.5% | 8.3% | 9.1% | 0.0% | 8.8% | 2.9% | 0.0% | 3.4% | 90.6% | 83.9% | 17.2% | | | | | |
| % Negative | 91.7% | 54.5% | 91.7% | 90.9% | 100.0% | 91.2% | 97.1% | 100.0% | 96.6% | 9.4% | 16.1% | 82.8% | | | | | |
| Consensus | Negative | Not Assessed | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | | | | |
| HLA Antibody Specificity (Defined By CDC) | A32 B44 DR7 | DQ3 | DR3 DR5 DR6 | A10 B16 DQ1 | A32 B44 DR7 | DQ3 | DR3 DR5 DR6 | A10 B16 DQ1 | A32 B44 DR7 | DQ3 | DR3 DR5 DR6 | A10 B16 DQ1 | | | | | |
| Lab No. | PBL Assessment | T Cell Assessment | B Cell Assessment | With DTT | | | | With DTT | | | | With DTT | | | | Comments | |
| | | | | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Serum 1 | Serum 2 | Serum 3 | Serum 4 | | |
| 101 | YES | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Negative | | |
| 112 | YES | | | NT | NT | NT | NT | | | | | | | | | Results not conclusive | |
| 114 | | YES | YES | | | | | Negative | Positive | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 116 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Positive | Dealted delivery. Low B-cell viability | |
| 119 | YES | | | Negative | Negative | Negative | Negative | | | | | | | | | | |
| 120 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 133 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 139 | YES | YES | YES | Negative | Positive | Negative | Positive | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 143 | | YES | | | | | | Negative | Negative | Negative | Negative | | | | | | |
| 147 | YES | YES | YES | Negative | Positive | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 157 | | YES | YES | | | | | NT | NT | NT | NT | | | | | | |
| 159 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 162 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 163 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 169 | | YES | YES | | | | | Negative | Positive | Positive | Negative | Negative | NT | Positive | Positive | Low viability and aggregates cells that not allowed a conclusive result | |
| 181 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 186 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Positive | | |
| 189 | YES | | | Negative | Negative | Negative | Negative | | | | | | | | | | |
| 190 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | NT | NT | NT | High B-cell mortality | |
| 193 | YES | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 194 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Equivocal | | |
| 195 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Positive | Cells arrives clustered in the sample | |
| 197 | | YES | YES | | | | | Negative | Positive | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 204 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Equivocal | Equivocal | Very low B-cell viability | |
| 206 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | Serum 4 B-cells - reaction between 2 and 4 | |
| 209 | YES | | YES | Negative | Negative | Negative | Negative | | | | | Negative | Positive | Positive | Negative | Low number of B-cells | |
| 216 | YES | | | Positive | Negative | Negative | Negative | | | | | | | | | | |
| 227 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | NT | Positive | NT | NT | Technical failure |
| 229 | YES | | | | | | | | | | | | | | | | No results returned |
| 235 | YES | | | Negative | NT | Negative | Negative | | | | | | | | | | Serum 2 is haemolysis |
| 238 | YES | YES | YES | Negative | Positive | Positive | Equivocal | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Positive | Positive | Serum 1 DQ6 MFI 7000 + DP6 MFI 7000 |
| 245 | YES | YES | YES | Negative | Positive | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 252 | YES | | | Negative | Negative | Negative | Negative | | | | | Negative | Positive | Positive | Negative | | |
| 260 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | NT | NT | NT | Low B-cell viability | |
| 262 | YES | YES | YES | Negative | Positive | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Positive | Positive | |
| 268 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | | |
| 284 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 292 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 293 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | | |
| 294 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 297 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Positive | | |
| 321 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | | |
| 351 | | YES | YES | | | | | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Heat inactivation instead of with DTT. Serum 2 was hemolyzed | |

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A03/2017 OS

DESPATCHED ON 28TH MARCH 2017

| Lab No. | PBL with DTT | | | | T-cell with DTT | | | | B-cell with DTT | | | | Cell viability % | | |
|---------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|------------------|---------|---------|
| | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | PBL | T-cells | B-cells |
| 101 | | | | | 1 | 1 | 1 | 1 | 1 | 8 | 1 | 1 | | | |
| 112 | NT | NT | NT | NT | | | | | | | | | 90 | | |
| 114 | | | | | 1 | 4 | 1 | 1 | 1 | 8 | 4 | 1 | | | |
| 116 | | | | | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | | 95 | 30 |
| 119 | 1 | 1 | 1 | 1 | | | | | | | | | 90 | | |
| 120 | | | | | 1 | 1 | 1 | 1 | 1 | 8 | 4 | 1 | | 100 | 100 |
| 133 | | | | | - | - | - | - | - | 8 | 8 | - | 95 | 95 | 95 |
| 139 | 1 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 1 | 80 | 80 | 80 |
| 143 | | | | | 1 | 1 | 1 | 1 | | | | | | 90 | |
| 147 | 1 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 1 | 100 | 100 | 100 |
| 157 | | | | | NT | NT | NT | NT | 1 | 8 | 6 | 1 | | 90 | 80 |
| 159 | | | | | 1 | 1 | 1 | 1 | 1 | 8 | 6 | 1 | | 100 | 85 |
| 162 | | | | | - | - | - | - | - | 8 | 8 | - | | 100 | 100 |
| 163 | | | | | 1 | 1 | 1 | 1 | 1 | 8 | 6-8 | 1 | | 98 | 98 |
| 169 | | | | | 1 | 4 | 4 | 1 | Equivocal | NT | 8 | 6 | | 90 | 90 |
| 181 | | | | | 1 | 1 | 1 | 1 | 2 | 8 | 6 | 2 | | 95 | 95 |
| 186 | | | | | 0 | 0 | 0 | 0 | 0 | 8 | 6 | 6 | | 95 | 90 |
| 189 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 95 | | |
| 190 | | | | | 1 | 1 | 1 | 1 | NT | NT | NT | NT | | 99 | 80 |
| 193 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 1 | 99 | 99 | 97 |
| 194 | | | | | - | - | - | - | - | - | - | Equivocal | | | |
| 195 | | | | | 2 | 2 | 2 | 2 | 2 | 6 | 6 | 4 | | 85 | 85 |
| 197 | | | | | - | Weak | - | - | - | - | Weak | - | | 80 | 80 |
| 204 | | | | | 1 | 1 | 1 | 1 | 6 | 8 | 6 | 6 | | 90 | 50 |
| 206 | | | | | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 2 | | 90 | 90 |
| 209 | 1 | 1 | 1 | 1 | | | | | 1 | 8 | 4 | 1 | | 90 | 85 |
| 216 | 4 | 1 | 1 | 1 | | | | | | | | | 95 | | |
| 227 | | | | | - | - | - | - | NT | 8 | NT | NT | | 90 | 90 |
| 229 | | | | | | | | | | | | | | | |
| 235 | 1 | NT | 1 | 1 | | | | | | | | | 85 | | |
| 238 | 1 | 4 | 4 | 2 | 1 | 1 | 1 | 1 | 2 | 8 | 6 | 4 | | 90 | 70 |
| 245 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 1 | 100 | 100 | 100 |
| 252 | 2 | 2-4 | 2 | 2 | | | | | 4 | 6-8 | 6 | 4 | | 80 | 70 |
| 260 | | | | | - | - | - | - | NT | NT | NT | NT | | 90 | 10 |
| 262 | 1 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 8 | 6 | 4 | 100 | 100 | 100 |
| 268 | | | | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | 95 | 50 |
| 284 | | | | | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 1 | | 99 | 85 |
| 292 | | | | | - | - | - | - | - | 6 | - | - | | 80 | 30 |
| 293 | | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | 70 | 70 |
| 294 | | | | | 0 | 0 | 0 | 0 | 0 | 8 | 8 | 2 | | 100 | 85 |
| 297 | | | | | 1 | 1 | 1 | 1 | 4 | 8 | 8 | 4 | 90 | 90 | 90 |
| 321 | | | | | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 1 | | 97 | 97 |
| 351 | | | | | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 100 | | |